Evomela

Plasmacytoma

M.D. Anderson Cancer CenterPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

4 Active assets in the Plasmacytoma cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Memorial Sloan Kettering Cancer Center	Phase 2	B
cc-5013 Memorial Sloan Kettering Cancer Center	Phase 2	B
Busulphan M.D. Anderson Cancer Center	Phase 2	B
Pomalidomide Mayo Clinic	Phase 2	B
Panobinostat M.D. Anderson Cancer Center	Phase 2	B

View all 12 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant

BBB

Indicative ·

76 / 100

myelodysplastic/myeloproliferative neoplasmDormant

BBB

Indicative ·

76 / 100

myeloproliferative neoplasmDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.